Methods of using bispecific antigen-binding constructs targeting HER2
US12157775B2 · kind B2 · utility
0Cited by
17References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 25, 2020 |
| Grant date | Dec 3, 2024 |
| Priority date | — |
| Expiry date | Jul 23, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described herein methods of using antigen-binding constructs to treat HER2+ tumors in a subject such as breast, lung, or head and neck tumors. In some aspects, the tumor volume in the subject after receiving at least seven doses of the antigen binding construct is less than the tumor volume of a control subject receiving an equivalent amount of trastuzumab. In some aspects, the survival of the subject receiving the antigen binding construct is increased as compared to a control subject receiving an equivalent amount of a non-specific control antibody or as compared to a control subject not receiving treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.